

Volume 13, Issue 4

Aug 2015 – Dec 2015

Due to travel restrictions and the need to reschedule the PBM-MAP-VPE Meetings where formulary decisions are made, this issue of the EZ Minutes combines two issues in one. Formulary Decisions from August 2015-December 11, 2015 are included in this issue.

Inside This Issue

Posting of National PBM Documents Aug-Dec 2015

Posting of VAMedSAFE Documents Aug- Dec 2015

National Contract Awards for CY 2015

Pharmacy-Prosthetics-Logistics and Acquisitions (PPL) Workgroup Aug-Dec 2015

TSOAC to DOAC

Reducing Polypharmacy in the Palliative Care Setting

PBM-MAP-VPE Webinars

Salute to former and New Members

Happy Holidays and a

Safe New Year

The purpose of PBM-MAP-VPE Ez-Minutes Newsletter is to communicate with the field on items which will impact clinical practice in the VA. Please send and feedback and/or comments to Janet.Dailey@VA.gov.

The recent issue of Ez Minutes can be read from your smart phone! Put the below link in your browser; hit search... and the current issue from the PBM INTERnet site will be ready to read. http://www.pbm.va.gov/PBM/ezminutes /current/currentEzMinutes.pdf

Don't forget...you can also subscribe to Ez-Minutes and any documents posted to the What's New Section on the PBM INTERnet web site by subscribing to the RSS Feed. http://www.pbm.va.gov/PBM/rss/Whats <u>New At PBM RSS Feed.xml</u>

Pharmacy Benefits Management-Medical Advisory Panel-VISN Pharmacist Executives

E_z - MINUTES

Watch for the next issue of Ez-Minutes Tuesday, March 1st, 2016 See us at: http://www.pbm.va.gov/ or https://vaww.cmopnational.va.gov/cmop/PBM/default.aspx.

Click Here to Subscribe to the Ez Minutes

Posting of National PBM Documents Aug – Dec 16, 2015 Formulary Decisions

ADDED to the VA National NOT ADDED to the National **Removed from the National** Formulary (VANF) Formulary (VANF) Formulary (VANF) 9-valent HPV vaccine • Antipyrine/benzocaine/glycerin Otic • Adapalene 0.3% and benzoyl peroxide • Bupropion XL (24-hour formulation) 2.5% topical gel combination Chloral hydrate Daclatasvir Afatinib Ipecac Syrup Idarucizumab Alemtuzumab • 4-valent HPV vaccine Lacosamide IV Alirocumab **Drug Monograph** • Lidocaine cream/ointment • Antihemophilic Factor (recombinant), • Lidocaine 5% patch Porcine Sequence Afatinib Melatonin (Certified Product Only) • Bosutinib Alemtuzumab • Paliperidone palmitate IM • Brimonidine Topical Gel Alirocumah • Buprenorphine Transdermal System • Phenylephrine (oral) Bosutinib Carbidopa Levodopa ER • Potassium Chloride oral solutionTechnivie Buprenorphine Transdermal System • Tiotropium/olodaterol Inhaler Ceftazidime/avibactam <u>Carbidopa Levodopa ER</u> · Ulipristal acetate Edoxaban Ceftazidime/avibactam • Flucinolone acetonide 0.19 intraviteral • Edoxaban implant Criteria for Use (CFU) • Empagliflozin (Pending: formulary • Glucagon Injection [synthetic] -the VANF status/update to the SGLT2 Inhibitor CFU) 9-valent HPV vaccine line item name will be changed to • Fluocinolone acetonide 0.19 intravitreal Glucagon Recombinant Injection to Acetylcholinesterase Inhibitors [Updated Dec. implant 2015] differentiate between synthetic glucagon • Idarucizumab Alemtuzumab (nonformulary) and recombinant • Insulin glargine 300U per mL • Alirocumab glucagon (formulary) • Ivabradine Hydrocodone bitartrate ER • Brimonidine Topical Gel Lacosamide Addendum Insulin glargine 300U per mL Carbidopa Levodopa ER Melatonin Daclatasvir Ivabradine Omacetaxine Mepesuccinate • Leuprolide acetate for depot injection • Ezetimibe/Ezetimibe+Simvastatin [Updated Ospemifene Nov. 2015] and norethindrone acetate • Ivabradine • Paclitaxel Protein-Bound Lidocane 5% ointment • Paliperidone palmitate IM Methylnaltrexone Injection [Updated Dec. 2015] Omacetaxine Mepesuccinate Paliperidone Ponatinib • Osemifene Pneumococcal 13 Valent Conjugate Sacubitril Valsartan • Oxycodone HCI Acetaminophen Vaccine [Updated Oct. 2015] • Tasimelteon Extended-Release Sacubitril Valsartan • Ticagrelor Addendum Paclitaxel Protein-Bound · Sofosbuvir and Ledipasvir-Sofosbuvir • Vortioxetine • Paroxetine mesylate 7.5 mg [Updated Oct. 2015; Dec 2015) Pasireotide Tasimelteon **Clinical Recommendations** Ponatinib • Ticagrelor [Updated Dec. 2015] Sacubitril Valsartan • Varenicline [Updated Dec. 2015] · Naloxone Kits and Autoinjector • Tasimelteon • Ulipristal acetate Vedolizumab Injection Vedolizumab Injection Viekira Pak and Technivie [Updated Dec. 2015] Additional Information Von Willebrand Factor/Coagulation Factor VIII Complex (human) Methylnaltrexone Injection guidances -Abbreviated Review indication for opioid-induced constipation Patient and Provider Letters 9-valent HPV vaccine in chronic noncancer pain was added • Hydrocodone bitartrate ER Oxcarbazepine-Not restricted to neuro Digoxin Patient Letter, Provider Letter Oxycodone HCI Acetaminophen Extended-(Digoxin has been removed from the VA Other Helpful Resources Release Drug Standardization List due to a shortage Cost Comparison for HCV Genotype 3 • Pasireotide of the active pharmaceutical ingredient • Technivie Regimens [InTRAnet only] Glatiramer Provider Letter and Patient • Tiotropium/olodaterol Inhaler Lidocaine 5% Patch Literature Review Letter

veds



- OmniPod Insulin Management System Recall: ADDENDUM [December 14, 2015]
- Auvi-Q (epinephrine injection, USP) Recall Potential Inaccurate Dosage Delivery [October 30, 2015]
- BD Syringes and Loss of Drug Potency: FDA Expands Warning-UPDATE [September 23, 2015]
 - OmniPod Insulin Management System Recall [September 5, 2015]
- Allergan Ophthalmic Product Recall Due to Particulate Matter: ADDENDUM [September 4, 2015]
 - Allergan Ophthalmic Product Recall Due to Particulate Matter [September 2, 2015] BD Syringes and Loss of Drug Potency [August 31, 2015]

National Contract Awards for Calendar Year 2015

Click on this link to view the National Contract Awards CY 2015. [InTRAnet only]

Pharmacy-Prosthetics-Logistics (PPL)* Workgroup

The table below depicts the various products reviewed during July-October 2015 meetings. The X marks which service(s) is responsible for managing the respective products. Please click HERE for previous recommendation and minutes made from earlier meetings.

	Products	Pharmacy+	Prosthetics+	Logistics+
*The PPL workgroup was created to help clarify the responsibility for management (e.g., ordering, storing, purchasing, and/or dispensing) of those products in which it is not clear which service should provide. The workgroup is not responsible for determining formulary status, clinical merit, or appropriate use of the products reviewed.	Anchor Arthrex Suture (permanent)		Х	
	Bio-adhesive glue and remover for facial prosthesis [Initial supply provide by prosthetics, replacement refills by pharmacy]	X (outpatients)	X (Initial)	
	Cefaly used for in migraines		X (outpatients)	
	Blood pressure devices/cuffs for home use		Х	
	Endoscopic Bariatric Therapy (gastric balloon)			Х
	Enteral declogging system (non-drug, e.g., ClogZapper and other similar products) if alternative agents (e.g., pancreatic enzyme products) are deemed ineffective or contraindicated	X (outpatient use)		X (inpatient or clinic use)
	Ful-Glo (fluorescein strips or drops)			X (inpatient or clinic use)
	GEM 21s, Osteogen and other similar resorbable boney void fillers			Х
	Lancets for blood glucose testing	X (outpatients)		X (inpatients and clinics)
	Oral care kit and suctioning system (e.g., Q-Care Kit containing chlorhexidine gluconate 0.12%)			X (inpatient or clinic use)
	Ovulation Kits for female Veterans	X (outpatient use)		
	Rocker cast boots/shoes or post-operative shoes		X (outpatients)	
	Rose Bengal			X (inpatient or clinic use)
	Sheepskin		X (outpatient use)	
	SPACEOAR (used prior to radiation of the prostate)			Х
	Vinyl or plastic pants to wear over adult diapers	X (in properly selected outpatients)	Х	

+Contingent upon approval from VISN or local Clinical Products Review Committee (CPRC). Implementation of these recommendations should be coordinated between services at local sites to ensure a smooth transition if recommendations lead to a change in responsible service. If you have any questions related to this announcement, please contact the responsible local service (Pharmacy, Prosthetics, or Logistics) for more detailed information.

NEW NAME DOAC

> The Scientific and Standardization Committee (SSC) of the International Society of Hemostasis and Thrombosis (ISTH) recently published recommendations on the use of consistent nomenclature for the newer class of oral anticoagulants that directly inhibit a single target and have similar clinical properties (e.g., dabigatran, rivaroxaban, apixaban, and edoxaban). After evaluation of several possibilities, the SCC of the ISTH recommends DOAC for direct oral anticoagulants. The nomenclature has been endorsed by several professional societies including the Anticoagulation Forum. (J Thromb Haemost.

TSOAC RENAMED TO DOAC (DIRECT ORAL ANTICOAGULANTS)

2015;13:1154-6) VA had widely adopted the target specific oral anticoagulants or TSOAC nomenclature (e.g., PBM documents, policy, CPRS ordering menus, MUET, etc.) as was originally endorsed by the Anticoagulation Forum and VA subject matter experts. Based on the new ISTH recommendations, the MAP and VPEs (National PBM) agreed that VA should transition from TSOAC to DOAC to be consistent with practices outside of VA.

The field will begin to see the new nomenclature of DOAC in PBM documents, communications, policy, MUET, etc. Facilities are encouraged to re-evaluate local and VISN level use of the TSOAC term and consider transitioning to the DOAC term. It may be helpful to include a reference to the former name of TSOAC (e.g., Direct Oral Anticoagulant [DOAC], formerly called TSOAC).

Reducing Polypharmacy in the Palliative Care Setting

Polypharmacy is a major risk factor for adverse medication reactions and interactions, particularly in the geriatric population. Despite this recognition, there is no uniform or consensus definition of polypharmacy although either "the use of 6 or more concomitant medications" or "use of a potentially inappropriate or unnecessary medication" has been frequently cited. Regardless of the definition employed, we know that there are many drivers of polypharmacy including:

- 1. Multiple disease specific guidelines in patients with multiple comorbidities
- 2. Treating acute problems in patients with multiple comorbidities (adding meds to meds)
- 3. Multiple providers involved in treating multiple comorbidities
- 4. Misinterpreting and mistreating adverse medication reactions (adding meds to meds)
- 5. Patient and family perception of medication necessity

How the process of deprescribing is communicated to the patient and family is also critical. Relating it to the goals of care discussion is usually the first step. If symptom relief and/ or functional status improvement are the major goals then many medications that do not contribute to achieving those goals can often be discontinued. The language used in this process is also very important – terms like, "optimize, individualize, limit pill burden, maximize benefit and minimize harm" are much better received than terms such as, "stopping, quitting, decrease cost, no longer covered, etc." As with all issues in Palliative Care, this <u>must be</u> a process of shared decision making so patients and families do not feel like they are being abandoned or that their treating clinicians are "giving up."

4

The most challenging issue to address is often item five, the patient and family perception of need for a whole host of medications that no longer may be helpful and can even be harmful. The most important way to address this issue is for treating physicians, in conjunction with palliative care consultants as needed, to frequently and systematically assess the **goals of care** for individual patients with serious and/or life-limiting illness. In many instances, if patients are primarily seeking symptom relief and/or maximization of overall functional status, then medications designed to prevent long term complications from chronic disease may no longer be appropriate. In those situations, a process of **"deprescribing"** should ensue, which is *defined as an effort to taper, reduce dose or stop medications in an effort to reduce polypharmacy, minimize adverse medication effects and avoid ineffective or even potentially harmful medications.*

In my experience, many patients who are taking six, eight or ten or more separate medications per day and often twice those numbers in terms of pills per day welcome the opportunity for this regimen to be streamlined. Furthermore, as most of us can attest to from experience, many patients do not feel worse as medications are withdrawn but may actually feel better, in which case it becomes much easier to convince them to reduce polypharmacy. The most common classes of medications where there is often great opportunity to "deprescribe" in the Palliative setting with a high likelihood that the benefit (including just reducing the pill "burden" and reducing cost of care) outweighs the harm include:

	Acetylcholinesterase Inhibitors (AChEI) may be efficacious in slowing disease progression for mild to moderate Alzheimer's Disease, less helpful and more harmful in
	advanced disease
	Memantine has small beneficial effect at six months only in moderate to advanced dementia and no clear added benefit in combo with AChEI
Dementia	Rivastigmine may help in Lewy Body disease but none of these agents are clearly helpful in vascular dementia and may be harmful in Frontotemporal dementia
Meds	Potential side effects including nausea, diarrhea, insomnia, and others not usually well tolerated in Palliative Care population
	It is safest to wean these medications over two weeks when stopping
	Highly prevalent in Palliative Care population (including those with metastatic cancer) for prevention of cardiovascular morbidity which often is no longer relevant
	• Recent study showed no difference in mortality at 60 days when statin is discontinued in Palliative Care setting (Kutner JS, etal. Safety and benefit of discontinuing statin
Statins	therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. (JAMA Intern Med. 2015; 175:691-700)
	Many Palliative Care patients have anorexia, weight loss or poor nutrition for which cholesterol lowering no longer makes sense
	• Is it treatment or prophylaxis of VTE, AFib, ischemic or valvular heart disease?
	• The role of prophylactic anticoagulation is limited in this setting
Anticoagulan	• The use is highly dependent on goals of care and bleeding risk versus (usually) low short term risk of thrombosis or stroke
& ASA	Inconvenience and cost of monitoring (warfarin) must be factors in the decision
	Bleeding risk of warfarin in patients with liver disease or metastasis and/or poor nutrition and low albumin can increase significantly
	• The main purpose of these agents is long-term reduction of heart failure, myocardial infarction, stroke, and kidney disease incidence which often become moot in
	Palliative Care setting
	The agents have minimal role in preventing or avoiding symptoms
Anti hyper-	• The risks for orthostasis, dehydration, falls and other adverse events or side effects are often higher in Palliative Care population
tensives	• If continued, the dose or number of agents can often be reduced and goal blood pressure can be less aggressive
	The main role for long-term prevention of micro and macrovascular disease often becomes moot in Palliative Care population
	• The risk of hypoglycemia often increases with occurrence of anorexia, decreased food intake and weight loss in many Palliative Care patients
	• Avoiding extremes of blood glucose is usually more sensible than "tight control" in Palliative Care setting
Insulin & oral hypoglycemic	Avoluting extremes of blood glucose is usually more sensible than lught control in Panlative care setting
meds	- Vitemic D and calcium for extension requestion on langer is relevant in most Palliotius Care nations
	 Vitamin D and calcium for osteoporosis prevention no longer is relevant in most Palliative Care patients Anemia of chronic disease is often misdiagnosed as iron deficiency leading to unnecessary supplementation and frequent GI side effects
	Aded oill burden and cost for little benefit
Vitamins, Iron, Supplements	Summary and Conclusion: Just as in the geriatric population, in the Palliative Care setting, a "less is more" approach to medication management
	is often the most sensible. While many patients and their clinicians tend to think of Palliative Care as akin to hospice and only dealing with patients

illnesses. While prognostication is fraught with hazard and uncertainty, one of the simple questions Palliative Care clinicians often ask when evaluating a patient is the so called "surprise" question: "Would I be surprised if this patient were not alive one year from now?" If the answer to this question is, "no" (and clinicians' gut response to this question is surprisingly accurate) then reconsidering the goals of medication therapy in these patients is very appropriate. Does it really make sense to continue medications designed to reduce mortality and mortality over many years when life expectancy is likely far less than that? Do the benefits of continuing a medication outweigh the risks (side effects, adverse events) and/or disadvantages (inconvenience, cost)? Is a given medication providing any *symptomatic* relief, or is it actually causing side effects or harm? Frequently reviewing the goals of care for patients with serious illness and engaging in effective communication and shared decision making to guide medication therapy and help achieve those goals is the optimal way to reduce polypharmacy and improve outcomes for Veterans.

Submitted by: Paul E. Stander, MD, MBA, FACP Director, Outpatient Palliative Care Phoenix, VAMC


Editor's Note: The PBM welcomes Dr. Stander as one of the newest member to the Medical Advisory Panel. Thank you for your contribution to the Ez-Minutes. Due to space constraint, this article was abbreviated. <u>Please click HERE to read the article in its entirety.</u>



All PBM-MAP-VPE webinars are conducted using the same Adobe Connect meeting link and VANTs number. <u>http://va-eerc-ees.adobeconnect.com/pbm-monthly-webinars/</u> VANTS: 1-800-767-1750 Access Code 49792#

Third Tuesday of the month @ 3 PM ET

NATIONAL PHARMACY BENEFITS MANAGEMENT



Virtual SERIES - RSSTECHS

If you missed any of the PBM webinars this year....Below are links to the taped 2015 PBM Webinars. JANUARY: Concomitant use of Benzodiazepines with Opioids http://va-eerc-ees.adobeconnect.com/p7ythol82cp/ FEBRUARY: Hepatitis C Updates http://va-eerc-ees.adobeconnect.com/p5cvv93l1ai/ **FEBRUARY: Naloxone Kit Updates** http://va-eerc-ees.adobeconnect.com/p2sq15b3ano/ MARCH: VA/DOD Clinical Practice Guidelines (CPG) for the Management of Dyslipidemia for CV Risk Reduction http://va-eerc-ees.adobeconnect.com/p5z7u4n3nd2/ **APRIL: Naloxone Kit Updates** http://va-eerc-ees.adobeconnect.com/p7h3jicoxqd/ MAY: Demystifying Statistics for the Clinician Part 1 http://va-eerc-ees.adobeconnect.com/p379bw4ocwr/ JUNE: Demystifying Statistics for the Clinician Part 2 http://va-eerc-ees.adobeconnect.com/p4maxlymnl8/ JULY: Naloxone Kit Updates http://va-eerc-ees.adobeconnect.com/p6jfco9rj2o/ AUGUST: Transforming Clinical Pharmacy Practice-Highlights from VHA Handbook 1108.01 http://va-eerc-ees.adobeconnect.com/p8bl401up4v/ SEPTEMBER: VA/DOD Clinical Practice Guidelines (CPG) for the Management of **Dyslipidemia for CV Risk Reduction** OCTOBER: Anticoagulation Series Part 1: Anticoagulation Surveillance http://va-eerc-ees.adobeconnect.com/p9h281rm7mj/ NOVEMBER: Anticoagulation Series Part 2: Anticoagulation Key Practices in VHA http://va-eerc-ees.adobeconnect.com/p6fj4rc39nk/ DECEMBER: PBM EdAC Education and Training Programs in 2016 http://va-eerc-ees.adobeconnect.com/p70stdfyari/ Board Certification Study Groups; DM Moodle Modules, How-To-Videos (Patient Education)

The PBM-MAP-VPE would like to thank and recognize the following members for their service to the VA and contributions to this committee:

Retired in 2015 Malcolm Weiss (VPE) Carl Hensley (VPE) Robert Rosenstein (MAP) Resigned in 2015

Lori Highberger (MAP) Welcome to the new

members in 2015:

Allen Blaivas (MAP) Shannon Kilgore (MAP) Karla Mallo (VPE) Paul Stander (MAP) Mark Donahue (MAP) Bruce Capehart (MAP) Matthew Schreiber (MAP)

Attention Pharmacist & Pharmacy Technicians Virtual VHA Board Certification Study Groups will start January 2016. Anyone can participate in the study group even if you are not interested in taking the exam. For additional information contact Janet, Dailey@va.gov and/or the POC for the following respective groups: BCPS: Kimberly.Schnacky@va.gov BCACP: Jonathan.Hoffman@va.gov BCOP: Lindsay.Kaster@va.gov BCCP: June.Griffith@va.gov CGP: Martin.Cruz@va.gov PTCB: Marta.Kane@va.gov/ and/or Jennifer.Suther@va.gov ON BEHALF OF THE **PBM-VPE-MAP** HAPPY HOLIDAYS HAPPY NEW YEAR!